

## Peer Review File

Article Information: <https://dx.doi.org/10.21037/tcr-23-1763>

### Reviewer A

Line 8: correct: "poor overall poor prognosis"

Reply: Corrected: overall poor prognosis

Line 19-20: authors reported "with or without durvalumab". However, authors must specify that control arm included placebo.

Reply: Changed to: with Durvalumab, a PD-1 inhibitor, or placebo

Line 20 "PD-L-1 inhibitor" must be corrected to "PD-L1 inhibitor"

Reply: corrected to "PD-L1 inhibitor"

Line 54-55 Author stated "In both studies, there was less benefit in patients with gallbladder cancer". However, it is not possible to compare the magnitude of benefit according to primary location. The benefit from ICI addition was observed also in galbladder cancer.

Reply: the statement was removed

- Please suggest novel potential biomarkers of response to ICI that should be further studied.

Reply: the data on potential biomarkers are still inconclusive. A statement on potential markers was added

- Please reformulate sentences 62-64.

Reply: Sentence was reformulated.

- Please correct formatting errors.

Reply: corrected

## Reviewer B

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): 3 a randomized, double-blind, placebo-controlled, phase 3 trial is a commentary on the current status of the first line systemic therapy in biliary tract cancers. The authors discussed two trials, KEYNOTE 966 and TOPAZ-1 trials, compared them, and gave reasonable conclusions. They did a good job of explaining that adding durvalumab or pembrolizumab is not necessarily a game changer. The observation of pembrolizumab for intrahepatic > extrahepatic, and vice versa for durvalumab is interesting.

Please consider the following changes to make it a better one.

### General

- Please make sure that references are at the end of the sentence with a space between the last letter and the reference.

Reply: references were added at the end of the sentence with the appropriate space

- Unless you use durvalumab at the beginning of the sentence, use lowercase d whenever it is used. Similarly, for pembrolizumab.

Reply: lowercase was used

- When you give us the OS or PFS difference, please give the p-value to let the readers know there is a significant difference between them.

Reply: P-value was added.

- Consider having at least 3-4 lines in a paragraph instead of 2 lines (e.g., lines 56-57).

Reply: line 56-57 were added to the previous paragraph

### Specific.

- You can use the abbreviation for overall survival in sentence 13 instead of using it from 21.

Reply: Abbreviation was used earlier in the text

- Combine the sentences in 29 and 30 instead of breaking it into a separate paragraph

Reply: sentences were combined

- Line 63, MSI was not abbreviated before this.

Reply: MSI was expanded

- Line 66 - consider expanding FGFR

Reply: FGFR was expanded

- A line or two comparing the adverse events between the trials (especially, between gem/cis vs gem/cis/ICI).

Reply: Lines were added regarding toxicities of interest